In fact, in some types of cancer, MCTs 1 and 4 are associated with a worse prognosis, while MCT2 expression seems to be diminished in aggressive tumours, being inclusively seen as a favourable prognosis marker for hepatocellular cancer [86]. This evidence concerns the gene SLC16A1 and hepatocellular carcinoma.